These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28698330)

  • 1. Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study.
    Andreasen RA; Kristensen LE; Ellingsen T; Christensen R; Baraliakos X; Wied J; Aalykke C; Ulstrup T; Schiøttz-Christensen B; Horn HC; Emamifar A; Duerlund B; Fischer L; Hansen IMJ
    BMJ Open; 2017 Jul; 7(7):e015536. PubMed ID: 28698330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol.
    Dalix E; Marcelli C; Bejan-Angoulvant T; Finckh A; Rancon F; Akrour M; De Araujo L; Presles E; Marotte H;
    BMJ Open; 2024 Sep; 14(9):e087872. PubMed ID: 39260856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study.
    Andreasen RA; Kristensen LE; Egstrup K; Baraliakos X; Strand V; Horn HC; Hansen IMJ; Christensen R; Ellingsen T
    Arthritis Res Ther; 2019 Oct; 21(1):221. PubMed ID: 31665083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certolizumab pegol for treating axial spondyloarthritis.
    Desmarais J; Beier S; Deodhar A
    Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathic pain in axial spondyloarthropathy is underdiagnosed and a confounding factor in biologic drug-switching decision: a cross-sectional study.
    Öğüt TS; Erbasan F; Terzioğlu ME; Aslan B; Çelik E; Yazisiz V
    Clin Rheumatol; 2023 May; 42(5):1275-1284. PubMed ID: 36746834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.
    Cantarini L; Fabbroni M; Talarico R; Costa L; Caso F; Cuneo GL; Frediani B; Faralli G; Vitale A; Brizi MG; Sabadini L; Galeazzi M
    Medicine (Baltimore); 2015 Jul; 94(30):e1170. PubMed ID: 26222847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?
    Kiltz U; Baraliakos X; Karakostas P; Igelmann M; Kalthoff L; Klink C; Krause D; Schmitz-Bortz E; Flörecke M; Bollow M; Braun J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1415-22. PubMed ID: 22505331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondyltis from a Single Rheumatology Hospital in Morocco.
    Akasbi N; Nihad S; Sofia Z; Khadija EK; Taoufik H
    Curr Rheumatol Rev; 2020; 16(3):240-244. PubMed ID: 30806321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
    Baraliakos X; Kiltz U; Peters S; Appel H; Dybowski F; Igelmann M; Kalthoff L; Krause D; Menne HJ; Saracbasi-Zender E; Schmitz-Bortz E; Vigneswaran M; Braun J
    Rheumatology (Oxford); 2017 Jan; 56(1):95-102. PubMed ID: 27997346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gait as predictor of physical function in axial spondyloarthritis: the prospective longitudinal FOLOMI (Function, Locomotion, Measurement, Inflammation) study protocol.
    Soulard J; Vuillerme N; Gaudin P; Grange L; Baillet A; Cracowski JL; Juvin R; Vaillant J
    Rheumatol Int; 2019 Oct; 39(10):1681-1688. PubMed ID: 31392500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis: Results From the SPARTAKUS Cohort.
    Mogard E; Olofsson T; Bergman S; Bremander A; Kristensen LE; Olsen JK; Wallman JK; Lindqvist E
    J Rheumatol; 2021 Nov; 48(11):1672-1679. PubMed ID: 33323532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial.
    Rusman T; van der Weijden M; Nurmohamed MT; van Denderen CJ; Landewé R; Bet PM; Bijl CV; van der Laken CJ; van der Horst-Bruinsma IE
    Scand J Rheumatol; 2023 Mar; 52(2):137-141. PubMed ID: 35543102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in pharmacotherapies for axial spondyloarthritis.
    Toussirot E
    Expert Opin Pharmacother; 2023; 24(13):1439-1448. PubMed ID: 37318776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.